Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study
B Pasternak, P Ueda, B Eliasson, AM Svensson… - bmj, 2019 - bmj.com
Objective To investigate the cardiovascular effectiveness of sodium glucose cotransporter 2
(SGLT2) inhibitors in routine clinical practice. Design Cohort study using data from …
(SGLT2) inhibitors in routine clinical practice. Design Cohort study using data from …
Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
Objective To compare the risk of cardiovascular events between sodium glucose
cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors among …
cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors among …
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
Objective To assess the association between the use of sodium glucose cotransporter 2
(SGLT2) inhibitors and seven serious adverse events of current concern. Design Register …
(SGLT2) inhibitors and seven serious adverse events of current concern. Design Register …
Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry
PM Becher, B Schrage, G Ferrannini… - European Journal of …, 2021 - Wiley Online Library
Aims Use of sodium–glucose co‐transporter 2 inhibitors (SGLT2i) in real‐world heart failure
(HF) is poorly characterised. In contemporary patients with HF and type 2 diabetes mellitus …
(HF) is poorly characterised. In contemporary patients with HF and type 2 diabetes mellitus …
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering …
Background In patients with type 2 diabetes and a high cardiovascular risk profile, the
sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have …
sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have …
Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study
Objective To assess the association between use of sodium-glucose co-transporter 2
(SGLT2) inhibitors and risk of serious renal events in data from routine clinical practice …
(SGLT2) inhibitors and risk of serious renal events in data from routine clinical practice …
Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis
Background The risks and benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors on
cardiovascular outcomes have not been well established. We pooled evidence from all …
cardiovascular outcomes have not been well established. We pooled evidence from all …
Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of …
WC Tsai, SP Hsu, YL Chiu, JY Yang, MF Pai, MJ Ko… - BMJ open, 2022 - bmjopen.bmj.com
Objectives To assess the cardiovascular and renal efficacy and safety of sodium-glucose
cotransporter-2 (SGLT2) inhibitors in patients without diabetes. Methods We searched …
cotransporter-2 (SGLT2) inhibitors in patients without diabetes. Methods We searched …
Cardiovascular outcomes of sodium glucose cotransporter‐2 inhibitors in patients with type 2 diabetes
Aims To determine the association between cardiovascular diseases (CVD) and SGLT2
inhibitors compared to sulfonylureas and dipeptidyl peptidase‐4 (DPP4) inhibitors and to …
inhibitors compared to sulfonylureas and dipeptidyl peptidase‐4 (DPP4) inhibitors and to …
Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study …
Background: Reduction in cardiovascular death and hospitalization for heart failure (HHF)
was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) …
was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) …